SAN DIEGO, June 6, 2017 /PRNewswire/ -- Shareholder rights law firm Johnson & Weaver, LLP has launched an investigation into whether the board members of Albany Molecular Research, Inc. (NASDAQ: AMRI) breached their fiduciary duties in connection with the proposed sale of the Company to The Carlyle Group and GTCR. Albany Molecular is contract research and manufacturing company that provides integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia.
On June 6, 2017, Albany announced it had signed a definitive agreement to be acquired by The Carlyle Group and GTCR. Under the terms of the agreement, The Carlyle Group and GTCR will acquire all of the outstanding shares of Albany common stock for $21.75 per share in cash.
The investigation concerns whether Albany's board failed to satisfy their duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Albany's shares of common stock.
If you are a shareholder of Albany and believe the proposed buyout price is too low or you're interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (jimb@johnsonandweaver.com) at 619-814-4471. If emailing, please include a phone number.
About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.
Contact:
Johnson & Weaver, LLP
Jim Baker, 619-814-4471
jimb@johnsonandweaver.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/albany-molecular-amri-alert-jw-investigates-price-and-process-of-proposed-sale-of-albany-molecular-research-inc-is-2175-a-fair-price-300469386.html
SOURCE Johnson & Weaver, LLP
